Gastric Cancer Clinical Trial
Official title:
Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial
Perioperative chemotherapy is the gold standard treatment in the resectable and advanced
gastroesophageal adenocarcinoma. The efficacy of this strategy has been demonstrated in two
randomized studies (1,2). It reduces tumour size before surgery, treats micrometastases and
evaluates chemosensitivity. Disease free and overall survival rates were significantly
improved with perioperative chemotherapy compared to surgery alone. However, the limitation
of these studies is that among all patients requiring chemotherapy, almost 70% of patients
will not have the complete sequence. This sequence is defined by the administration of 2 to
4 cycles before and 2 to 4 cycles after the surgery, according to the protocol. The major
cause of absence or impossibility of realization of postoperative chemotherapy was the
presence of postoperative complication, postoperative serious asthenia and impaired
nutritional and physical status (1,2). Poor physical condition assessed by cardiopulmonary
exercise testing, reflecting a reduced physiological reserve, is predictive of postoperative
complications (3,4). A physical training, even during a short period and on a various
population, is beneficial in improving physical condition, cardiopulmonary function and
muscular mass of the patient (5-8). A prehabilitation over a 6 week period between surgical
consultation and surgery decreases postoperative morbidity and the hospital stay in
cardiovascular surgery but no study has ever been performed in the gastric or oesophageal
cancer (7,9).
Prehabilitation revolves around three axes: 1) a physical training based on initial
cardiopulmonary exercise testing (VO2peak, anaerobic threshold (AT) and 6-min walk test
(6MWT)), 3 times by week, supervised by a physical therapist 2) a nutritional care to ensure
the compliance of the nutrition program and adapt the nutritional management based on
protein and energy needs and on the level of spontaneous oral intake and 2) a psychological
treatment by a psychologist to reduce preoperative anxiety. To our knowledge, no study ever
focused on the gastroesophageal cancer. The benefit of prehabilitation in this cancer may be
particularly important because 1) this surgery is associated with a high postoperative
morbidity (40%, especially respiratory) and mortality (5%) 2) the physical and nutritional
status of these patients is often precarious (cancer cachexia, gastroesophageal
obstruction), and 3) the need to preoperative chemotherapy declines physical reserves and is
associated with a lengthening of the time between consultation and surgery of more than 3
months (10). Also, the investigators hypothesize that with a physical training, a
personalized nutritional support and a psychologist management may decrease postoperative
complications, increase postoperative nutritional status and so, would allow for more
patients to receive their full cancer treatment. The aim of this study was to evaluate, in
gastroesophageal adenocarcinoma, the effect of prehabilitation compared to conventional
care, the percentage of patients reaching the complete oncological treatment decided in a
multidisciplinary tumour board.
Interventions After the first visit with his surgeon, the patient will be presented at the
multidisciplinary tumour board to validate the inclusion criteria and to schedule the number
of cycles of pre- and postoperative chemotherapy. After this step, a second consultation
with the surgeon will allow to verify all inclusion and exclusion criteria and perform the
randomization. For the two groups, an initial (before chemotherapy) and final (one week
before the surgery) evaluation will be performed. The evaluation includes cardiopulmonary
exercise testing (VO2peak, AT and 6MWT), nutritional evaluation (albumin), bioelectric
impedance analysis, evaluation of physical activity and ingesta, evaluation of the level of
depressive symptoms and anxiety with the HADS questionnaire and the quality of life (5Q-FD
questionnaire).
Prehab group Exercise intervention: The total-body exercise will consist of up to 1 hour of
supervised exercise for at least 3 days per week, for a total of 18 cycles, alternating
between aerobic and resistance training. Exercise intensity will be prescribed based on the
rate of the 6MWT, AT and VO2peak. The participant will exercise in the presence of the
kinesiologist who will provide corrective feedback if necessary.
Nutrition intervention: Initially, a nutritionist will perform a medical and biological
examination of the nutritional status to provide individualized care to each patient.
Individual protein requirements will be calculated as 1.2 g of protein per kilogram of body
weight (adjusted body weight was used for obese patients), as per European Society for
Clinical Nutrition and Metabolism (ESPEN) guidelines, regarding surgical patients (12).
Patients will be asked to consume the protein supplement within one hour of their exercise
regimen to capitalize on postexercise muscle protein synthesis (13). Then, a dietician will
assess the compliance of the nutritional support at each cycle of chemotherapy and will
adjust it if necessary. After the preoperative chemotherapy, a second evaluation by a
nutritionist will be performed.
Psychologist intervention: Patients will receive up to a one hour visit with a trained
psychologist who will provide techniques aiming to reducing anxiety, such as relaxation
exercises based on imagery and visualization, together with breathing exercises. Each
patient will practice these exercises with the psychologist initially and at each cycle of
chemotherapy and at home two to three times per week. The psychologist also provides
suggestions on how to enhance and reinforce patients' motivation to comply with the exercise
and nutritional aspects of the intervention.
Control group:
The control group will be treated according to conventional care; will not receive any
specific intervention before surgery except nutritional support and physiotherapy at the
surgeon's discretion.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |